Clinical Trials Browser

HER2-positive Metastatic Breast Cancer × 1 year × Clear all

NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

HER2-positive Metastatic Breast Cancer

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

HER2-positive Metastatic Breast Cancer

NCT06595563 2026-02-19

ZEPHIR-02

Phase 2 Recruiting

HER2-positive Metastatic Breast Cancer